Ubs Group Ag Biomarin Pharmaceutical Inc Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ubs Group Ag holds 13,000 shares of BMRN stock, worth $875,939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,000
Previous 385,542
96.63%
Holding current value
$875,939
Previous $31.7 Million
97.12%
% of portfolio
0.0%
Previous 0.01%
Shares
31 transactions
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.53 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.3 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.27 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$936 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$707 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.5B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...